NewTimeSpace News: On July 6, 2026, RoboSense (02498.HK) trended downward during morning trading. As of 11:21, the stock was quoted at HK$23.68, down 6.11%. YOUIBOT officially unveiled Xifeng, its brand-new industrial-native humanoid robot equipped with mini 360° digital LiDAR tailor-made by RoboSense for robots.
Hong Kong stocks experienced a volatile week, with the LLM sector exhibiting extreme divergence. XUNCE, Baidu, and Meituan led the gains, bolstered by strategic partnerships, subsidiary IPO prospects, and flagship product launches. Conversely, MiniMax and KNOWLEDGE ATLAS suffered heavy weekly losses, dragged down by lock-up anxieties and a global tech sell-off triggered by Meta's plans to lease surplus AI compute. Landmark industry shifts emerged: globally, the AI capital cycle is pivoting toward refined operational efficiency, while OpenAI launched its GPT-5.6 series under restricted access. Domestically, Kuaishou's Kling AI secured a record-breaking USD 3 billion funding, Meituan open-sourced its trillion-parameter LongCat-2.0 model trained entirely on domestic chips, and SAMR introduced seven national AI agent standards, collectively accelerating the commercialization and compliant deployment of foundational models.
On July 3, Hong Kong equities trended higher, with the HSI advancing 1.28%. Driven by Unitree Robotics' record-breaking STAR Market IPO approval, robotics concept stocks erupted, propelling Horizon Robotics and Estun Automation significantly higher. AI applications diverged, and the semiconductor sector corrected, while KNOWLEDGE ATLAS gained 2.2%. In major capital developments, global AI is signaling a shift toward operational efficiency as Meta plans to lease surplus AI computing and Anthropic negotiates custom chips with Samsung. Domestically, Kuaishou's Kling AI raised up to USD 3 billion at a USD 18 billion valuation—setting a global financing record for video models—while XUNCE launched a concurrent convertible bond and H-share placement to raise HKD 2.35 billion.
NewTimeSpace News: Sino Biopharmaceutical Limited (01177.HK) announced on 3 July that the New Drug Application (NDA) for its Class 2.2 new drug ropivacaine hydrochloride sustained-release solution has been accepted, which is developed for long-acting postoperative analgesia. As the world’s first long-acting ropivacaine preparation administered via wound coating, it can deliver sustained analgesia for up to 72 hours. Phase III clinical trials demonstrated superior efficacy versus control agents with favourable overall safety profiles.
NewTimeSpace News: On July 3, 2026, XPENG-W(09868.HK) fluctuated downward in the afternoon trading session. As of 14:14, its intraday quotation stood at HK$51.25, representing a drop of 1.06%. XPeng delivered 40,126 new vehicles in June 2026, bringing its total quarterly deliveries to 103,295 units in the second quarter of 2026.
NewTimeSpace (newtimespace.com) reported that on July 3, 2026, the chip theme rebounded in trading, while SMIC (00981.HK) fluctuated lower. As of 14:02, the stock was quoted at HKD 78.200, down 2.74%.
In July 2026, CSC Financial covered Mininglamp Technology for the first time and granted it a "Buy" rating. The firm believes that the company is at a critical period of strategic transformation from traditional data intelligence to Agentic AI, and that its new business, Agentic Services, delivered high growth immediately upon its launch in the second half of last year.
NewTimeSpace (newtimespace.com) reported that on July 3, 2026, the robotics theme continued to strengthen, with UBTECH (09880.HK) rising sharply. As of 13:37, the stock was quoted at HKD 105.400, up 13.82%.
NewTimeSpace News: EDDING GENOR GROUPannounced in a July 2 announcement that the Investigational New Drug (IND) application for GB268, its highly differentiated innovative PD-1/CTLA-4/VEGF trispecific antibody, has been approved by the National Medical Products Administration (NMPA) for a Phase Ib/II clinical trial treating locally advanced unresectable or metastatic breast cancer.
NewTimeSpace News: Hanx Biopharmaceuticals announced on July 2 that the Company has signed a cooperation agreement with Swiss biotechnology firm TwinEdge Bioscience to conduct translational medical research on its core bispecific antibody candidate HX009 leveraging AI technologies.
NewTimeSpace News: Brii Biosciences announced on July 3 the end-of-treatment results from its Phase 2b ENRICH and ENHANCE studies. Data from the ENRICH trial showed that regimens with initial BRII-179 followed by combination therapy of elebsiran and PEG-IFNα achieved HBsAg clearance rates of 42.9% and 40.0% respectively.
NewTimeSpace News: The United Laboratories International Holdings Ltd (03933.HK) announced that tadalafil tablets (specifications: 5mg, 10mg, 20mg) filed by Zhongshan Branch of Zhuhai United Laboratories, its wholly-owned subsidiary, have obtained marketing approval from the National Medical Products Administration, indicated for the treatment of erectile dysfunction and erectile dysfunction accompanied by benign prostatic hyperplasia.
NewTimeSpace News: HUTCHMED (China) Limited (00013.HK) issued a voluntary announcement stating that ORPATHYS® (savolitinib), its proprietary oral MET inhibitor, has obtained conditional marketing approval from the National Medical Products Administration (NMPA) of China for adult patients with locally advanced or metastatic gastric or gastroesophageal junction (GC/GEJ) adenocarcinoma harbouring MET gene amplification, who have failed at least two lines of prior systemic therapy. This marks the third approved indication of savolitinib in China.
NewTimeSpace News: CSPC Pharmaceutical Group Limited (01093.HK) issued a voluntary announcement disclosing that the Group has entered into a collaboration, option and licence agreement with AstraZeneca. The parties will jointly develop preclinical candidate compounds (PCCs) targeting two therapeutic targets with potential for treating kidney diseases, leveraging the Group’s proprietary siRNA drug discovery platform and extrahepatic targeted delivery platform. CSPC will receive an upfront payment of USD30 million, plus potential development milestone payments of up to USD540 million, sales milestone payments of up to USD1.2 billion, and single-digit royalties on net annual sales of commercialised products.
NewTimeSpace News: On July 2, 2026, BIDU-SW(09888.HK) ticked slightly higher in afternoon trading. As of 15:00, its intraday price stood at HK$109.9, representing a gain of 0.27%. With the national standard for autonomous driving published, the compliant commercial rollout of high-level autonomous driving under the new rules requires full-chain capabilities covering "self-developed algorithms, massive scenario data, full-process simulation testing, safety system verification and closed-loop standardized filing management", lifting entry thresholds across the sector.
NewTimeSpace (newtimespace.com) reported that on July 2, 2026, the semiconductor theme in Hong Kong stocks continued to decline in the afternoon, with HUA HONG GRACE (01347.HK) falling sharply. As of 13:42, the stock was quoted at HKD 186.500, down 13.34%.
